Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023662 | 1.00 | HDAC8 (0.31) | HDAC8HDAC6HRH3HDAC1ADORA2A | |
| SCHEMBL14365491 | 0.73 | — | — | |
| SCHEMBL1605358 | 0.72 | — | — | |
| SCHEMBL10249613 | 0.71 | HDAC8 (0.30) | HDAC8HDAC6HDAC1 | |
| SCHEMBL14440597 | 0.71 | HDAC8 (0.30) | HDAC8HDAC6HDAC1 | |
| SCHEMBL1606082 | 0.70 | — | — | |
| SCHEMBL1606160 | 0.67 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL1386152 | 0.65 | FYN (0.35) | — | |
| SCHEMBL8981701 | 0.64 | HDAC8 (0.38) | HDAC8HDAC6HDAC1CASP3 | |
| SCHEMBL8981710 | 0.64 | HDAC8 (0.38) | HDAC8HDAC6HDAC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1753736-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HDAC8 1228/4885HDAC6 987/4885HRH3 1268/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | HDAC8 1154/4885HDAC6 1240/4885HRH3 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.